Cancer Immunology

Cancer Immunology refers to the relationship between immune function and cancer. The immunological mechanisms involved in cancer growth are highly complex and provide numerous potential points for intervention with small molecules, including extracellular enzymes, receptors and intracellular signal transduction pathways.

Cancer Immunology Products Targets

Products for Cancer Immunology - Page 5

Cat.No. Product Name Information/Activity
BCC7646 AZ 11645373 Potent and selective human P2X<sub>7</sub> antagonist
BCC7717 5-BDBD 768404-03-1
BCC6815 Evans Blue tetrasodium salt Selective P2X purinergic antagonist,Evans Blue is a potent inhibitor of L-glutamate uptake via the membrane bound excitatory amino acid transporter (EAAT).
BCC3602 KN-62 KN-62 is a selective and potent inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with IC50 of 0.9 μM, KN-62 also displays noncompetitive antagonism at P2X7 receptors in HEK293 cells, with an IC50 value of approximately 15 nM.
BCC6985 NF 023 104869-31-0
BCC7404 NF 110 111150-22-2
BCC7367 NF 157 NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively. NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA).
BCC6964 NF 279 202983-32-2
BCC7043 NF 449 Highly selective P2X<sub>1</sub> antagonist
BCC6725 PPADS tetrasodium salt PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca²⁺exchanger in guinea pig airway smooth muscle.